At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 244 enrolled
Drug / intervention
Varilrix (inactivated varicella vaccine)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Two Formulations of GSK Biologicals' Varicella Vaccine Given as a 2-dose Course in the Second Year of Life
In Brief
A Phase 2 clinical trial evaluating Varilrix (inactivated varicella vaccine) for Varicella. Completed, enrolled 244 participants across 13 sites in 2 countries.
Detailed Summary
The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety. This present study is undertaken to rule out any negative impact on the immunogenicity and safety of GSK Biologicals' live attenuated varicella virus vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaricella
CountriesCzechia, Hungary
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedDec 2007
Primary CompletionMar 2008
Study CompletionApr 2008
TodayJul 2026
First PostedDec 6, 2007
Enrollment StartNov 1, 2007
Primary CompletionMar 18, 2008
Study CompletionApr 29, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.6 years ago
Interventions
Varilrix (inactivated varicella vaccine)biological
subcutaneously injection